theory clinical_105_9
imports Main

begin

typedecl entity
typedecl event

consts
  Trastuzumab :: "entity ⇒ bool"
  HER2 :: "entity ⇒ bool"
  ExtracellularDomain :: "entity ⇒ bool"
  Bind :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Specifically :: "event ⇒ bool"
  Mutation :: "entity ⇒ bool"
  IntracellularDomain :: "entity ⇒ bool"
  Affect :: "event ⇒ bool"
  HER2V777L :: "entity ⇒ bool"
  IntracellularTyrosineKinaseDomain :: "entity ⇒ bool"
  Located :: "event ⇒ bool"
  Target :: "event ⇒ bool"
  Resistance :: "entity ⇒ bool"
  Location :: "entity ⇒ bool"
  Specific :: "entity ⇒ bool"
  In :: "entity ⇒ entity ⇒ bool"
  Lead :: "event ⇒ bool"
  AntibodyTherapy :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  To :: "entity ⇒ entity ⇒ bool"
  Prevent :: "event ⇒ bool"
  Protein :: "entity ⇒ bool"
  Effectively :: "event ⇒ bool"
  Therapy :: "entity ⇒ bool"

(* Explanation 1: Trastuzumab binds specifically to the HER2 extracellular domain, and this binding does not affect mutations located in the intracellular kinase domain. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. Trastuzumab x ∧ HER2 y ∧ ExtracellularDomain y ∧ Bind e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Specifically e1 ∧ Mutation z ∧ IntracellularDomain z ∧ Affect e2 ∧ Agent e2 x ∧ Patient e2 z ∧ ¬Affect e2"

(* Explanation 2: The HER2 V777L mutation is located in the intracellular tyrosine kinase domain, which is not targeted by trastuzumab, leading to resistance. *)
axiomatization where
  explanation_2: "∃x y z e1 e2. HER2V777L x ∧ Mutation x ∧ IntracellularTyrosineKinaseDomain y ∧ Located e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Trastuzumab z ∧ Target e2 ∧ Agent e2 z ∧ Patient e2 y ∧ ¬Target e2 ∧ Resistance y"

(* Explanation 3: The specific location of the HER2 V777L mutation in the intracellular tyrosine kinase domain directly leads to resistance to trastuzumab because trastuzumab does not target the intracellular domain. *)
axiomatization where
  explanation_3: "∃x y z e1 e2. HER2V777L x ∧ Mutation x ∧ IntracellularTyrosineKinaseDomain y ∧ Location z ∧ Specific z ∧ In z y ∧ Lead e1 ∧ Agent e1 z ∧ Patient e1 y ∧ Resistance y ∧ Trastuzumab z ∧ Target e2 ∧ Agent e2 z ∧ Patient e2 y ∧ ¬Target e2"

(* Explanation 4: The HER2 V777L mutation may cause resistance to antibody therapy because it is located in the intracellular domain, which trastuzumab does not target. *)
axiomatization where
  explanation_4: "∃x y z e1 e2. HER2V777L x ∧ Mutation x ∧ Resistance y ∧ AntibodyTherapy z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ To y z ∧ IntracellularDomain x ∧ Located e2 ∧ Agent e2 x ∧ Patient e2 x ∧ Trastuzumab z ∧ Target e2 ∧ Agent e2 z ∧ Patient e2 x ∧ ¬Target e2"

(* Explanation 5: The location of the HER2 V777L mutation in the intracellular tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain and does not affect the intracellular domain. *)
axiomatization where
  explanation_5: "∃x y z e1 e2 e3. HER2V777L x ∧ Mutation x ∧ IntracellularTyrosineKinaseDomain y ∧ Location z ∧ In z y ∧ Lead e1 ∧ Agent e1 z ∧ Patient e1 y ∧ Resistance y ∧ Trastuzumab z ∧ Target e2 ∧ Agent e2 z ∧ Patient e2 y ∧ ExtracellularDomain y ∧ Affect e3 ∧ Agent e3 z ∧ Patient e3 y ∧ ¬Affect e3"

(* Explanation 6: The HER2 V777L mutation prevents trastuzumab from effectively targeting the HER2 protein, resulting in resistance to the therapy. *)
axiomatization where
  explanation_6: "∃x y z e1 e2. HER2V777L x ∧ Mutation x ∧ Trastuzumab y ∧ HER2 z ∧ Protein z ∧ Prevent e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Target e2 ∧ Agent e2 y ∧ Patient e2 z ∧ Effectively e2 ∧ Resistance z ∧ Therapy z"

theorem hypothesis:
  assumes asm: "HER2V777L x ∧ Trastuzumab z"
  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)
  shows "∃x y z e1 e2 e3. HER2V777L x ∧ Resistance y ∧ Trastuzumab z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ To y z ∧ Bind e2 ∧ Agent e2 z ∧ Patient e2 x ∧ ExtracellularDomain x ∧ Mutation x ∧ IntracellularDomain x ∧ In x z"
proof -
  (* From the known information, we have HER2V777L x and Trastuzumab z. *)
  from asm have "HER2V777L x ∧ Trastuzumab z" by auto
  (* We have a logical relation Implies(C, E), which states that if the HER2 V777L mutation is located in the intracellular tyrosine kinase domain, it leads to resistance to trastuzumab. *)
  (* Explanation 2 provides that the HER2 V777L mutation is located in the intracellular tyrosine kinase domain. *)
  from explanation_2 have "HER2V777L x ∧ Mutation x ∧ IntracellularTyrosineKinaseDomain y ∧ Resistance y" sledgehammer
  (* Therefore, we can infer resistance to trastuzumab. *)
  then have "Resistance y" <ATP>
  (* Explanation 1 states that trastuzumab binds specifically to the HER2 extracellular domain. *)
  from explanation_1 have "Trastuzumab z ∧ Bind e2 ∧ Agent e2 z ∧ Patient e2 x ∧ ExtracellularDomain x" <ATP>
  (* Combining these, we can show the hypothesis. *)
  then show ?thesis <ATP>
qed

end
